FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/07/2022
Voltar para busca
Dado oficial do USPTO
ORPHALAN INNOVATION FOR ORPHAN DISEASES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
05/07/2022
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10, 42, 44
Data de depósito
09/09/2020
Data de registro
28/12/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/12/2021
Última transação
28/12/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
33
Localização do titular
FR
Examinador
BETTS, MARCYA
Unidade examinadora
L60
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a navy blue drop and light purple drop facing each other at its points. To the top left of the drops is a sky blue square with its upper left vertex rounded. To the bottom right of the drops is a purple circle. To the right of the aforementioned elements is the stylized navy blue wording "ORPHALAN" followed by a grey vertical band with the stylized stacked sky blue wording "INNOVATION FOR ORPHAN DISEASES" following the vertical band.
Titulares e representantes
Titulares
ORPHALAN
Representantes
Heather R. Smith-Carra Banner & Witcoff, Ltd.
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
diagnostic agents for pharmaceutical use; capsules sold empty for pharmaceutical use; pharmaceutical compounds for the treatment of orphan diseases; pharmaceutical products for the treatment of orphan diseases; chemical preparations for pharmaceutical usefor the treatment of orphan diseases; chemical preparations for medical usefor the treatment of orphan diseases; medicines for the development of treatment for orphan diseases
Classe 10
Medical apparatus and instruments for diagnosing and treating orphan diseases; surgical apparatus and instruments; diagnostic apparatus for medical use for diagnosing orphan diseases; immunochemical testing apparatus for medical use; medical testing instruments for diagnosing and treating orphan diseases; substance analysis apparatusmedical devices and medical instruments for the analysis of body fluids; instruments for extraction of liquids from the human bodymedical devices for obtaining body fluid samples; blood testing apparatus; radiology apparatus for medical use; blood testing instrumentsneedles for medical use and veterinary use; resuscitation apparatus; gloves for medical use; gloves for veterinary use; syringes for medical use; fluid injectors for medical use; X-rays for medical use; inhalers for medical use; radiology screens for medical use; containers for applying medicines being medical tubing for administering drugs; special containers for medical waste; probes for medical use; thermometers for medical use; medical casescases fitted for medical instruments; stethoscopes; heart pacemakers; electromagnetic diagnostic imaging apparatus for medical use; needles for medical use
Classe 42
Development of pharmaceutical preparations and medicines; development of pharmaceutical products; providing information on clinical studies for pharmaceutical products via an interactive website; evaluation of pharmaceutical products; scientific research in the field of pharmacy; research regarding pharmaceutical products; pharmaceutical research and development; research relating to pharmaceutical products; research and development for the pharmaceutical industry; conducting clinical trials for other in the field of pharmaceutical products; pharmaceutical drug development services; laboratory research services relating to pharmaceutical products; pharmaceutical research services; medical and pharmacological research services; pharmaceutical research and development services; Scientific research for medical purposes; scientific laboratory services; research and development in the field of biotechnology; design and development of medical diagnostic apparatus
Classe 44
Advice relating to pharmacyadvice relating to the use of pharmaceuticals for the treatment of orphan diseases; advisory services relating to health; pharmaceutical advice; advice relating to medicines; information to patients on administering medicines; medical information; drug use testing service for medical use; pharmaceutical servicespharmaceutical compounding services and information services relating to diagnosticprophylactic and therapeutic properties of pharmaceutical products; medical testing and analysis services for diagnostic or treatment of orphan disease; health advisory services relating to the use and operation of medical apparatus and instruments for treatment of orphan disease; medical diagnosis of orphan diseases
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/06/2022
FIMP
FINAL DISPOSITION PROCESSED
09/06/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
28/03/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
28/12/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/10/2021
PUBO
PUBLISHED FOR OPPOSITION
12/10/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/09/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/09/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
03/09/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/09/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
03/09/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/09/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/08/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/08/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/08/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
22/04/2021
GNFR
FINAL REFUSAL E-MAILED
22/04/2021
CNFR
FINAL REFUSAL WRITTEN
22/04/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
10/04/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
26/03/2021
RFNT
REFUSAL PROCESSED BY IB
01/03/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/02/2021
RFRR
REFUSAL PROCESSED BY MPU
08/02/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/01/2021
CNRT
NON-FINAL ACTION WRITTEN
27/01/2021
DOCK
ASSIGNED TO EXAMINER
19/01/2021
MAFR
APPLICATION FILING RECEIPT MAILED
30/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/10/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
22/10/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ORPHALAN INNOVATION FOR ORPHAN DISEASES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.